Skip to content
Screener

Dianthus Therapeutics DNTH Q1 2026 earnings

Reported May 5, 2026 · After market close

Revenue$463.0KBeat by $59.4K
EPS-$0.85Beat by $0.32
Revenue estimate$403.6K
EPS estimate-$1.17

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$443.9K
EPS estimate-$0.94

Financials

Q1 2026

Income statement

See full
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$4.44B+662%
Enterprise value$3.82B+565%

Returns & leverage

See full
Debt / equity0×0.0×
Current ratio29.3×+13.3×

Segments

By product

See full
License$463.0K-60.2%

FAQ

When did Dianthus Therapeutics report Q1 2026 earnings?
Dianthus Therapeutics (DNTH) reported Q1 2026 earnings on May 5, 2026 after market close.
What were Dianthus Therapeutics's Q1 2026 revenue and EPS?
Dianthus Therapeutics reported revenue of $463.0K and eps of $-0.85 for Q1 2026.
Did Dianthus Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $403.6K by $59.4K. EPS beat the consensus estimate of $-1.17 by $0.32.
How did Dianthus Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 60.2% from $1.2M a year earlier and eps declined 3.7% from $-0.82.
Where can I find Dianthus Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001690585-26-000021) and the 10-Q periodic report (0001690585-26-000022) directly on SEC EDGAR. The filing index links above go to sec.gov.